Ulcerative colitisBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7242.1119 (Published 22 April 2000) Cite this as: BMJ 2000;320:1119
- Subrata Ghosh, consultant (email@example.com),
- Alan Shand, specialist registrar,
- Anne Ferguson, professor
- Gastrointestinal Unit, Department of Medical Sciences, University of Edinburgh and Western General Hospital, Edinburgh EH4 2XU
- Correspondence to: S Ghosh
Ulcerative colitis is a relapsing and remitting disease characterised by acute non-infectious inflammation of the colorectal mucosa. In the United Kingdom the annual incidence is around 7cases per 100 000 population.1 The rectal mucosa is invariably affected. Confluent inflammation and shallow ulceration extend proximally from the anal margin. A patient may have proctitis, left sided colitis (the proximal limit being below the splenic flexure), extensive colitis (involving the transverse colon), or pan colitis. At any point in time, 50% of patients are asymptomatic, 30% have mild symptoms, and 20% have moderate to severe symptoms.2 Many patients have long periods of complete remission, but the cumulative probability of remaining free from relapse at two years is only 20%, decreasing to less than 5% at 10 years.3 Later relapses generally affect the same region of the colon as previous episodes.
Several of the current clinical and therapeutic issues in ulcerative colitis include: (a) medical treatment options for relapse and for maintenance of remission; (b) management of the minority of patients who develop a severe life threatening relapse or chronic unremitting disease; (c) surgical treatment of ulcerative colitis; and (d) long term complications in patients with extensive disease—namely, colonic and biliary cancers and sclerosing cholangitis.
Ulcerative colitis may present at any age, but the anatomical distribution of involvement at presentation is different between children and adults
All patients with bloody diarrhoea need to have infection excluded
Outpatient rigid sigmoidoscopy is the best method of diagnosing the nature of inflammation
The extent of inflammation may be established by total colonoscopy (or a double contrast barium enema)
The mainstays of treatment are rectal and systemic 5-aminosalicylic acid derivatives and corticosteroids, with azathioprine in steroid dependent or resistant cases
Restorative proctocolectomy with ileal pouch-anal anastomosis should be considered in every patient in whom …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial